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Among theknowngenetic risk factors forParkinsondisease,mutations inGBA1, the gene responsible for the lysosomaldisorderGaucher
disease, are themost common.This genetic linkhas directed attention to the role of the lysosome in thepathogenesis of parkinsonism.To
study how glucocerebrosidase impacts parkinsonism and to evaluate new therapeutics, we generated induced human pluripotent stem
cells from four patientswith Type 1 (non-neuronopathic) Gaucher disease, twowith and twowithout parkinsonism, and one patientwith
Type 2 (acute neuronopathic) Gaucher disease, and differentiated them into macrophages and dopaminergic neurons. These cells
exhibited decreased glucocerebrosidase activity and stored the glycolipid substrates glucosylceramide and glucosylsphingosine, dem-
onstrating their similarity topatientswithGaucherdisease.Dopaminergic neurons frompatientswithType2 andType1Gaucherdisease
with parkinsonism had reduced dopamine storage and dopamine transporter reuptake. Levels of -synuclein, a protein present as
aggregates in Parkinson disease and related synucleinopathies, were selectively elevated in neurons from the patientswith parkinsonism
or Type 2 Gaucher disease. The cells were then treated with NCGC607, a small-molecule noninhibitory chaperone of glucocerebrosidase
identified by high-throughput screening and medicinal chemistry structure optimization. This compound successfully chaperoned the
mutant enzyme, restored glucocerebrosidase activity and protein levels, and reduced glycolipid storage in both iPSC-derived macro-
phages and dopaminergic neurons, indicating its potential for treating neuronopathic Gaucher disease. In addition, NCGC607 reduced
-synuclein levels in dopaminergic neurons from the patients with parkinsonism, suggesting that noninhibitory small-molecule chap-
erones of glucocerebrosidase may prove useful for the treatment of Parkinson disease.
Key words: -synuclein; dopaminergic neurons; glucocerebrosidase; induced pluripotent stem cells; parkinsonism; pharmacological
chaperone
Significance Statement
Because GBA1mutations are the most common genetic risk factor for Parkinson disease, dopaminergic neurons were generated
from iPSC lines derived from patients with Gaucher disease with and without parkinsonism. These cells exhibit deficient enzy-
matic activity, reduced lysosomal glucocerebrosidase levels, and storage of glucosylceramide and glucosylsphingosine. Lines
generated from the patients with parkinsonism demonstrated elevated levels of-synuclein. To reverse the observed phenotype,
the neurons were treated with a novel noninhibitory glucocerebrosidase chaperone, which successfully restored glucocerebrosi-
dase activity and protein levels and reduced glycolipid storage. In addition, the small-molecule chaperone reduced -synuclein
levels in dopaminergic neurons, indicating that chaperoning glucocerebrosidase to the lysosomemay provide a novel therapeutic
strategy for both Parkinson disease and neuronopathic forms of Gaucher disease.
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Introduction
Mutations in GBA1, the gene mutated in Gaucher disease (GD),
are the most frequent known genetic risk factor for the common
neurodegenerative disorders Parkinson disease (PD) and demen-
tia with Lewy bodies (DLBs). GD is caused by the inherited defi-
ciency of the enzyme glucocerebrosidase (GCase, E.C.3.2.1.45),
which hydrolyzes the glycolipids glucosylceramide (GlcCer) and
glucosylsphingosine (GlcSph), and is characterized by lysosomal
storage of these substrates. GD is classified into three types based
on the absence (Type 1) or rate of progression of neurologic
manifestations (Types 2 and 3). Type 2 GD is a progressive and
lethal disorder of infancy or early childhood (Weiss et al., 2015).
Studies of cohorts from around the world demonstrate that
patients with PD and DLB are far more likely to carry mutations
in GBA1 than controls (Sidransky et al., 2009; Nalls et al., 2013).
Furthermore, patients with GD and their carrier relatives have an
increased risk of both PD and DLB (Tayebi et al., 2003; Goker-
Alpan et al., 2004).
While the appreciation of this association has directed atten-
tion to the role of the lysosome in these neurodegenerative dis-
orders, the pathological mechanisms by which mutations in
GBA1 contribute to parkinsonism remain unclear. Theories pro-
posed implicate enhanced levels of-synuclein (-syn), a protein
with a propensity to aggregate, as well as sphingolipid accumula-
tion and impaired intracellular trafficking, all of which may play
a role in the pathogenesis of neurodegeneration (Mazzulli et al.,
2011; Siebert et al., 2014). There is increasing evidence of an
inverse relationship between levels of GCase and -syn in the
brain, as GCase levels and activity are diminished even in idio-
pathic PD (Gegg et al., 2012; Murphy et al., 2014). Clinically,
GBA1-associated parkinsonism in homozygotes or carriers often
mirrors sporadic PD with regard to the presence of tremor, bra-
dykinesia, and rigidity (Schapira, 2015) as well as in imaging
studies. However, some patients manifest clinical and imaging
features and pathology consistent with DLB (Kono et al., 2010;
Saunders-Pullman et al., 2010; Goker-Alpan et al., 2012). Both
PDandDLB are synucleinopathies, characterized by the accumu-
lation of LBs containing aggregated -syn, albeit in different an-
atomic distributions. Thus, amajor therapeutic goal is to identify
strategies to prevent aggregation or to facilitate the clearance of
aggregated proteins.
The inverse relationship between GCase and -syn led us to
posit that enhancement of GCase activity, a therapeutic strategy
under development for GD, could also have implications for the
treatment of PD. While many symptoms of GD are effectively
treated with enzyme replacement therapy or substrate reduction
therapy, these costly therapies are ineffective for neuronopathic
forms ofGD (Altarescu et al., 2001). Pharmacological chaperones
have been proposed as an alternative therapy for GD, including
neuronopathic forms, and potentially for PD (Sawkar et al., 2006;
Richter et al., 2014). Such drugs are designed to bind to mutant
GCase and facilitate its refolding and subsequent trafficking to
the lysosome. Using high-throughput screening, we identified
two series of compounds, a thiazide series and a new salicylic acid
series, which successfully translocate GCase to the lysosome and
can cross into the brain (Goldin et al., 2012; Aflaki et al., 2014).
However, it has been difficult to evaluate the effects of such drugs,
especially in neurons, due to the scarcity of appropriate cellular
models.
Induced pluripotent stem cells (iPSCs) offer an opportunity
to study functional dopaminergic neurons derived from patients
with GD and PD. In this study, we differentiated iPSCs from
patients with non-neuronopathic GD (GD1), GD with parkin-
sonism (GD1-PD), and acute neuronopathic GD (GD2) into do-
paminergic (iDA) neurons andmacrophages (iMacs). These new
models have enabled us to evaluate GCase activity and protein
levels, intracellular dopamine (DA) content andmetabolism, and
-syn levels. These cells were also treated with a new noninhibi-
tory GCase chaperone, enabling us to assess the ability of this
compound to correct the cellular phenotype. Utilizing the iMacs
and iDAneurons derived fromour patients, we demonstrate how
targeting glucocerebrosidase activity in these models provides
insight into disease pathogenesis, identifying new avenues for the
development and evaluation of drugs for GD and potentially PD.
Materials andMethods
Synthesis of NCGC607. Synthetic reactions (see Fig. 1) were performed
under an atmosphere of dry argon or nitrogen. All anhydrous solvents,
commercially available starting materials, and reagents were purchased
from Sigma-Aldrich. Analytical thin-layer chromatography (TLC) was
performed using Sigma-Aldrich thin-layer chromatography plates (5
20 cm, 60 Å, 250 m). Visualization was accomplished by irradiation
under a 254 nm UV lamp. Reverse-phase preparative purification was
performed on a Waters semipreparative high-performance liquid chro-
matography (HPLC) system (Column: Phenomenex Luna C185 m,
30  75 mm) at a flow rate of 45 ml/min; mobile phase consisted of
acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gra-
dient of 10%–50% acetonitrile over 8 min was used during the purifica-
tion. Fraction collection was triggered by UV detection (220 nM). 1H
spectra were recorded on a Varian Inova 400MHz spectrometer. Chem-
ical shifts are reported in ppm with the solvent resonance as the internal
standard (DMSO-d6 2.50 ppm, for
1H). Data are reported as follows:
chemical shift, multiplicity (s  singlet, d  doublet, t  triplet, q 
quartet, br s broad singlet, m  multiplet), coupling constants, and
number of protons. Molecular weights were confirmed using an Agilent
Time-Of-FlightMass Spectrometer (Agilent Technologies). A 3min gra-
dient from 4% to 100% acetonitrile (0.1% formic acid) in water was used
with a 4 min run time at a flow rate of 1 ml/min. A Zorbax SB-C18
column (3.5 m, 2.1  30 mm) was used at 50°C. Molecular formula
were confirmed using electrospray ionization in the positive mode with
the Agilent Masshunter software (Agilent Technologies, version B.02).
Patient samples. Six iPSC lines were derived from patients with GD1
andGD2with differentmutations and from an adult control (Table 1) as
described previously (Aflaki et al., 2014). All were generated from fibro-
blasts taken from individuals evaluated clinically for up to a decade by a
Movement Disorder specialist at the Clinical Center of the National In-
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Table 1. Genotypes of patients with Gaucher disease used for iPSC lines
Genotype Gender Age
GD1-1 N370S/N370S Sib1 Male 64 yr
GD1-PD1 N370S/N370S Sib2 Male 62 yr
GD1-2 N370S/N370S Male 66 yr
GD1-PD2 N370S/c0.84dupG Male 59 yr
GD2 IVS21GT/L444P Female 9 mo
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stitutes of Health. Participants provided informed consent under a Na-
tional Human Genome Research Institute Institutional Review Board-
approved protocol. Two of the patients with GD1 also developed PD.
Patient GD1-PD1 with genotype N370S/N370S was diagnosed with PD
at the age of 52. His brother (GD1–1), also with genotype N370S/N370S,
and now 64 years old, has GD but no manifestations of PD. Patient
GD1-PD2 with genotype N370S/c.84dupG developed parkinsonian
manifestations at age 45 and died at age 59 with a postmortem diagnosis
of DLB.
Differentiation of iPSCs to monocytes and macrophages. Differenti-
ation of iPSCs to monocytes and the macrophages, performed to
establish compound efficacy, was described previously (Aflaki et al.,
2014). In summary, embryoid bodies (EBs), formed using AggreWell
400 plates (Stem Cell Technology), were transferred to ultra-low ad-
herence plates in AggreWell medium supplemented with 10 M
ROCK inhibitor (Stem Cell Technology) for 4 d, with daily media
changes. For differentiation to monocytes, EBs were transferred to
gelatin (1%)-coated 6 well plates, in Advanced DMEM (Invitrogen)
supplemented with 10% FCS, 0.055mM -mercaptoethanol, 50 ng/ml
M-CSF, and 25 ng/ml IL-3 (R&D Systems). Media was replaced every
3 d. Monocytes were harvested from the supernatant, centrifuged at
1500 rpm for 5 min, and differentiated into iMacs using RPMI sup-
plemented with 10% FCS and 100 ng/ml M-CSF.
Differentiation of iPSC to dopaminergic neurons. iPSCs were detached
and cultured in AggreWell 800 (Stem Cell Technology) for 5 d. The
resulting EBs were seeded into plates coated with polyornithine/laminin
for 6 d. At day 11, typical neural tube-like rosettes appeared and were
detached using STEMdiff Neural Rosette Selection (Stem Cell Technol-
ogy). Rosettes were cultured into poly-ornithine/laminin-coated plates
and differentiated to neuronal progenitor cells (NPCs). Then, differen-
tiation to dopaminergic neurons was performed based on the protocol of
Hartfield et al. (2014). All growth factors were obtained from Peprotech,
unless otherwise stated. Briefly, neuronal induction medium I (DMEM/
F12 supplemented with L-glutamine [2 mM], N2 supplement, BSA [1
mg/ml], Y27632 [10 M; Tocris Bioscience], SB431542 [10 M, Tocris
Bioscience] and noggin [200 ng/ml]) was added to the NPCs for 3 d and
then media was changed at day 4 by withdrawing SB43152 and noggin
and adding 200 ng/ml sonic hedgehog [SHH C24II], fibroblast growth
factor-8a (FGF8a, 100 ng/ml), and ascorbic acid (200 M; Sigma) for
10 d. Cells could then be passaged and were maintained in their final
differentiation media (DMEM/F12 supplemented with L-glutamine [2
mM], N2 supplement, BDNF [20g/ml], and glial-derived neurotrophic
factor [GDNF, 20 g/ml]). For most experiments, cells were kept in
culture for100 d.
Immunofluorescence staining. iDA were plated on glass chamber slides
coated with poly-ornithine/laminin and iMacs, fed with erythrocyte
ghosts in the presence and absence of NCGC607, were plated on glass
chamber slides and fixed with 4% PFA. Cells were blocked in PBS con-
taining 0.1% saponin, 100 M glycine, and 2% donkey serum, followed
by incubation with the primary antibody. They were washed and incu-
bated with donkey anti-mouse or anti-rabbit secondary antibodies and
conjugated to Alexa-488 or Alexa-555 (Invitrogen). Cells were mounted
with Vectashield plus DAPI (Vector Laboratories) and Z-stack images
were acquired with a Zeiss 510 META laser scanning microscope (Carl
Zeiss) using a 488 argon, a 543 HeNe, and a UV laser. Images were
acquired using 63 a PlanNeoFluar lens.
Immunoblotting. iDA neurons were harvested and sonicated at 4°C in
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Na-
deoxycholate, 0.1% SDS, and protease inhibitor). After quantification
with BCA (Thermo Scientific), 10 g of the lysates was separated by
Novex NuPAGE SDS-PAGE Gel System (Invitrogen) and transferred to
iBlot PVDF membranes (Invitrogen). Blots were blocked in 1:1 PBS,
Odyssey Blocking Buffer (Li-COR Bioscience) for 1 h at room tempera-
ture. The membrane was incubated in blocking buffer containing 0.1%
Tween 20 (Sigma), and respective primary antibodies: MAO-A (10539-
1-AP) and MAO-B (12602-1-AP) (Abcam), -syn (Santa Cruz Biotech-
nology, sc-7011-R) and Tuj1 (Cell Signaling Technology, 5568),
overnight at 4°C, followed by three 15 min washes, and was incubated in
blocking buffer containing 0.1% Tween 20 (Sigma), 0.01% SDS, and
IRDye 680RD secondary antibody 1:10,000 (Li-COR Bioscience) for 1 h
at room temperature. The blot was imaged using an Odyssey imaging
system (Li-CORE Bioscience) and quantified using Image Studio Lite
software.
GlcCer and GalCer analysis bymass spectrometry.An aliquot of iMac or
iDA cell pellet, homogenized inwater, was spikedwith internal standards
(C17 S1P, N,N-dimethylpsychosine, GalCer(d18:1 8:0)) and extracted
with methanol. One portion of the extract was used for quantification of
GlcSph, and GlcCer using reverse-phase C18 columns for HPLC/MS/
MS. The other portion of the extract was used for the determination of
GlcSph and GalSph as well as GlcCer and galactosylceramides (GalCer)
using an HILIC column.
Measurement of catecholamine metabolites by HPLC. iDAs were col-
lected in 400 l 20:80 (40 mM H2PO4: 200 mM acetic acid) and dis-
rupted by freezing and thawing. The catechols were extracted from
200 l by alumina adsorption and were detected and quantified by
HPLC with electrochemical detection as described previously (Gold-
stein et al., 2012).
Evaluation of DA uptake .Dopamine update in iDA neurons was mea-
sured using a neurotransmitter transporter uptake assay kit (Molecular
Devices). This kit uses fluorescent substrate that mimics the biogenic
amine transmitters resulting in increased intracellular fluorescence in-
tensity. Cells were cultured in clear-bottom black plates and were treated
with 10 or 20MGBR1209 (Tocris Bioscience) for 10min inHBSS buffer
supplemented with 0.1% BSA to allow binding of the compound to the
transporter. Dye solution was added to the cells and fluorescence (Ex/
Em, 440/520) was measured kinetically for 30 min at 37°C.
GCase activity and protein levels. iDA neurons were lysed in citrate-
phosphate extraction buffer. To exclude activity from other nonlyso-
somal GCases, lysates were incubated with or without 100 M CBE, an
inhibitor specific for GBA1, for 30 min and the amount of uninhibited
activity was subtracted from the total. Assay buffer (1 M 4-MU -glu to a
final concentration of 10 mM in citrate-phosphate buffer) was added for
90min at 37°C. The reaction was halted using a stop solution (1 MNaOH
and 1 M glycine) and fluorescence measured. To measure GCase protein
levels, lysates were incubated with 100 nM green fluorescent MDW933,
an irreversible inhibitor (Witte et al., 2010), for 90 min at 37°C. After a
brief centrifugation, lysates were subjected to SDS-PAGE electrophore-
sis. Wet gels were scanned using a Typhoon Variable Mode Imager (ex
488 nm and em 520 nm).
Electrophysiology. Cultured cells were placed in a heated recording
chamber (31°C-33°C) and perfusedwith ACSF containing 125mMNaCl,
25 mM NaHCO3, 1.25 mM NaH2PO4, 3.5 mM KCl, 1 mM MgCl2, 2 mM
CaCl2, and 10 mM glucose bubbled with 95/5% O2/CO2. Current-clamp
and voltage-clamp recordings were made with a Multiclamp 700B am-
plifier and digitized with a Digidata 1440A (Molecular Devices). Low-
resistance patch electrodes (3–5M)were pulled fromborosilicate glass. In
voltage-clamp recordings, pipette series resistance was compensated by
65%–75%. Internal recording solution contained the following: 122 mM
K-methanesulfonate, 9 mMNaCl, 1.8 mMMgCl2, 4 mMMg-ATP, 0.3mM
Na-GTP, 14 mM phosphocreatine, and 10 mM HEPES adjusted to pH
7.35 with NaOH.
RNA isolation and real-time PCR. A total of 1 g total RNA, isolated
frommacrophages using the PrepEase RNA/Protein Spinkit (Affymetrix
78767), was reverse transcribed using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, 4368814). Quantitative real-time
PCR was performed using an ABI prism 7900 real-time PCR instru-
ment (Applied Biosystems). Expression of -syn was performed using
TaqMan (Applied Biosystems) with HPRT as an internal control. Two
independent experiments were performed.
Statistical analysis. Statistical analyses were performed using Graph-
PadPrism5.0 software. Significance was determined by a Student’s t test
using a Wilcoxon signed rank test. Correlations were determined using
Pearson correlations. Data from two groups or2 independent variables
were analyzed by ANOVA, followed by the Bonferroni post hoc test. Data
are presented as mean SD values.
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Results
NCGC607, a new noninhibitory chaperone, increases GCase
and reduces GlcCer levels in Gaucher macrophages
NCGC607, a salicylic acid derivative, is a noninhibitory small-
molecule chaperone that belongs to a chemical series first identi-
fied by high throughput screening using a patient spleen sample
as the source of mutant human GCase (Goldin et al., 2012). The
specific compound NCGC607 was discovered using medicinal
chemistry to improve the activity of mutant GCase in the screen-
ing assay (Fig. 1).
The cellular phenotype of GD primarily manifests in macro-
phages, where excessive glucosylceramide (GlcCer) accumulates
in lysosomes due to defective digestion of erythrocyte or white
blood cell membranes. Therefore, to establish the ability of this
new compound to chaperone GCase, we first evaluated the effect
of NCGC607 using iPSC-derived patient macrophages (iMacs),
produced as described previously (Aflaki et al., 2014). In iMacs
derived from patients with genotype N370S/N370S (GD1) and
IVS2  1GT/L444P (GD2), treatment with 3 M NCGC607
significantly enhanced GCase activity and increased GCase
levels (Fig. 2A,B). In the presence of NCGC607, GD iMacs
showed decreased levels of GlcCer (Fig. 2C) and enhanced
translocation of GCase to the lysosome (Fig. 2D,E). Together,
these data indicate that NCGC607 effectively chaperoned
GCase, increasing translocation, enhancing enzyme activity,
and reducing GlcCer levels.
Gaucher iPSC-dopaminergic neurons appropriately
recapitulate the human phenotype with diminished GCase
activity and levels
Next, we differentiated our six iPSC lines to iDA neurons using a
modified published protocol (Kriks et al., 2011). The EBs in the
colony center developed a columnar morphology, and, after 4 d
in culture, became organized into neural-tube-like rosettes
(Fig. 3A), which expressed Sox1, an early transcription factor
expressed in ectodermal cells committed to a neuronal fate (Pe-
vny et al., 1998). Rosette-containing clusters were expanded to
formNPCs, which stained positive for neuronalmarkers FOXA2,
Nestin, and neuron-specific -III-tubulin (Tuj1). After 12 d of
differentiation, most cells expressed PITX3, FOXA2, and AADC
mRNA (Fig. 3B). The GD1 and GD1-PD NPCs showed the ex-
pected reduction in GCase activity (30% of control levels),
whereas the GD2 NPCs had 2% GCase activity (Fig. 3C). All
had correspondingly low levels of GCase protein (Fig. 3D). The
neurons were further differentiated to iDA neurons, and immu-
noflorescence staining confirmed that they expressed Map2,
Tuj1, and the iDA marker TH (Fig. 3A,D,E).
iPSC-derived iDA neurons appear to be
biologically functional
To establish that these were indeed iDA neurons, we examined
catecholamine metabolism, exploring storage, release, and up-
take in cells kept in culture for 100 d. Figure 4A shows the
Figure1. Synthesis of NCGC00241607. The synthesis of NCGC00241607 (NCGC607)was executed according to the schemeabove. A synopsis of the procedure used in each transformation is given
along with the synthetic yield and 1H NMR, 13C NMR, and HRMS data characterizing NCGC607.
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capacity of synthesis and release of DA in iPSC-derived iDA neu-
rons using HPLC to measure the intracellular levels of both DA
and 3,4-dihydroxyphenylacetic acid. Compared with controls,
there is reduced intracellular DA in GD1-PD and GD2, but not
GD1, iDA neurons.
DA uptake is reduced in Gaucher iDA neurons from patients
with parkinsonism
Next, DA uptake was measured in iDA neurons kept in culture
for 150 d in the presence or absence of GBR1209, a selective
inhibitor of the DA transporter (DAT). DAT, expressed in iDA
neurons, pumps the neurotransmitter DA out from the synapses,
returning it to the cytosol. Administering either 10 or 20 M
GBR1209 for 30 min, we observed reduced DA uptake in GD1
and GD1-PD iDA neurons. However, in GD1-PD neurons, DA
uptakewas lowered furtherwith 20MGBR1209 (Fig. 4B).While
DAT1 is expressed in iDA neurons (Fig. 4C), mRNA levels of
DAT1 were reduced in the GD1-PD, but not the GD2 or GD1
iDA neurons (Fig. 4D). iDA neurons also express the vesicular
monoamine transporter 2 (VMAT2) (Fig. 4E), which is respon-
sible for packaging DA into cellular compartments (Nirenberg et
al., 1996).We found that VMAT2mRNA levels were also lower in
GD1-PD iDA neurons (Fig. 4F). Overall, these data indicate that
DA uptake was reduced in GD1-PD iDA neurons. Electrophysi-
ology studies also indicated that the iPSC-derived iDA neurons
were functional. After 40 d in culture, they fired and showed
appropriate action potentials in response to injected current us-
ing a patch clamp, exhibiting voltage-gated sodium and potas-
sium currents (Fig. 4G).
Treatment of Gaucher iDA neurons with NCGC607 increased
GCase activity, enhanced translocation of mutant GCase to
the lysosome, and reduced substrate levels
GD1, GD1-PD, and GD2 iDA neurons were cultured for 100 d
and then treated with the small-molecule NCGC607 for 21 d.
GCase levels, reduced in GD iDA neurons, improved after treat-
ment with NCGC607 (Fig. 5A,B). The residual GCase activity in
GD1, GD1-PD, and GD2 iDA neurons was 40 1.2%, 25.35
2.07%, and 2 0.2% of control activity, respectively. In the pres-
ence of NCGC607, GCase activity increased two-fold in GD1 and
1.8-foldGD1-PD iDAneurons. InGD2 iDAneurons treatedwith
NCGC607, GCase activity increased 40-fold (Fig. 5C).
In iDA neurons from each patient with GD, treatment with
compound NCGC607 resulted in markedly increased translo-
cation of GCase to the lysosome (Fig. 5D), as reflected by
enhanced colocalization of GCase with the lysosomal marker
Lamp2 (Fig. 5E).
Next, levels of GlcSph, a toxic substrate of GCase especially
abundant in the brain, were measured using mass spectrometry
in iDAneurons held in culture for150 d. iDA neurons from the
Figure 2. NCGC607 enhances GCase activity and facilitates its translocation to lysosomes in Gaucher macrophages. A, GCase activity in the presence of different concentrations of NCGC607
measured in iMacs from a control and iPSC line GD1–1 (N370S/N370S). Graph represents two independent experiments. RFU, Relative fluorescence units.B, Western blot analysis of GCase in iMacs
from two subjects with GD1 (N370S/N370S) and one with Type 2 with and without NCGC607 (3 M for 6 d). Control iMacs (C) are shown on the right. -Actin is used as the loading control.
Quantification of the results as the ratio of GCase to-actin appears in the graph below. C, GlcCer levels weremeasured using HPLC/MS/MS in control and iMacs from the iPSC lines indicated. Graph
represents two independent experiments (each experiment in triplicate). Statistically significant differences betweenpatient and control values: *p 0.03; **p 0.0092 and p 0.0046; ***p
0.0005.D, Immunofluorescence study of iMacs treatedwith NCG607 (3M) for 6 d and costained for GCase (green), lysosomalmarker Lamp2 (red), and nuclearmarker DAPI (blue). Z-stack images
wereacquiredusingaZeiss 510 confocalmicroscope (63magnification). Scalebars, 5m.E, Pearson’s coefficientwasquantified reflecting thedegreeof colocalizationbetweenGCaseandLamp2
using Imaris software. Each data point represents the mean value of the cells in a field.
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two subjects with GD1 alone had 15-fold and 10-fold  0.09
higher levels of GlcSph than control iDA neurons. iDA neurons
from the two subjects withGD1-PD showed 16.2 0.04-fold and
36.2 0.18 elevations in GlcSph, whereas in GD2 iDA neurons,
GlcSph levels were 45.3  0.19 times higher than control. The
accumulation was specifically related to GCase deficiency, as
the vast majority of sphingosine detected was GlcSph and not
GalSph (Fig. 6B). Treatment with NCGC607 resulted in sig-
nificantly reduced GlcSph levels in all five GD lines, indicating
that the enhanced translocation of mutant GCase increased
GlcSph hydrolysis (Fig. 6C).
GlcCer levels, evaluated by both mass spectrometry (Fig.
6A,D) and immunostaining (Fig. 6E), were significantly elevated
in aged GD1, GD1-PD, and GD2 iDA neurons. Treatment with
NCGC607 resulted in a reduction of GlcCer levels, particularly
in GD1-PD and GD2 iDA neurons (Fig. 6D). Staining of iDA
neurons with an antibody against GlcCer confirmed the accu-
mulation of GlcCer in the lysosomes of GD1, GD2, and
GD1-PD iDA neurons, which was reduced after treatment
with NCGC607 (Fig. 6E).
-Syn accumulation in GD-PD iDA neurons is reversed
with NCGC607
The observation that reducedGCase leads to-syn accumulation
in cultured neurons (Mazzulli et al., 2011) prompted us to study
levels in our iDAneurons, kept in culture for150 d. Staining for
the iDAneuronalmarker TH and for-syn (Fig. 7A) showed that
-syn is present both in the neurite and cell body in GD iDA
neurons, whereas in control neurons -syn was only observed in
neurites. Moreover, while -syn protein levels were elevated in
GD1-PD andGD2, but notGD1 iDAneurons (Fig. 7B,C), we did
not observe significant differences in mRNA levels between GD
and GD-PD iDA neurons (Fig. 7D). Next, we stained aged iDA
neurons for Lamp2 and -syn and found colocalization of -syn
Figure 3. Differentiation of iDA neurons from GD or GD-PD iPSCs. A, Each iPSC line was differentiated into rosettes (first panel), NPCs (second panel), and then iDA neurons and analyzed by
immunofluorescence staining during the different stages of differentiation. Stains include antibodies to Sox1 (red), Nestin/FoxA2/TuJ1 (green/red/pink), Nestin/Map2 (red/green), and Map2/TH
(red/green). B, RT-PCR analysis of PIRX3, FOXA2, AADC, and HPRT (control) gene expression levels in NPCs and iDA neurons from four of the lines. C, GCase activity (percentage of control) was
measured in NPCs from the iPSC lines indicated. Graph represents data from two independent experiments in quadruplicate. ***p 0.0003 and p 0.00022.D, Western blot analysis of GCase in
NPCs, using the GCase-specific irreversible inhibitor MDW933. Tuj1 and-actin were used as loading controls. E, Western blot analysis of TH levels in iDA neurons after 100 d in culture. A total of
10g of protein was loaded per lane.
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with Lamp2 in GD1-PD and GD2 iDA
neurons indicating the presence of -syn
in lysosomes. Treating aged iDA neurons
with NCGC607 resulted in reduced -syn
levels in GD1-PD and GD2 iDA neurons
and reduced colocalization of -syn with
Lamp2 (Fig. 7E,F).
Discussion
It is increasingly clear that glucocerebro-
sidase plays a role in the pathogenesis of
different forms of parkinsonism, as muta-
tions in GBA1 are a common genetic risk
factor for PD and DLB, and both GBA1
homozygotes and heterozygotes are at
risk (Sidransky et al., 2009; Nalls et al.,
2013). Moreover, patients with idiopathic
PD also appear to have decreased GCase
levels. In this study, we generated and
characterized iPSC-derived dopaminer-
gic neurons from patients with GD and
GD1-PD to further investigate this associ-
ation. Although iPSC-iDA have been
generated from subjects withGBA1muta-
tions previously (Scho¨ndorf et al., 2014;
Woodard et al., 2014; Sun et al., 2015; Fer-
nandes et al., 2016), our study is unique,
as we compared lines from subjects with
GD with and without PD, including one
set of siblings with genotype N370S/
N370S who were discordant for PD. This
enabled us to better discriminate which
aspects of the observed cellular phenotype
were specifically associatedwith the devel-
opment of parkinsonism. We also com-
pared a line from a child with GD2 to
those with GD1 and identified differences
that could be related to the pathogenesis
of neuronopathic GD. Furthermore, all
lines were generated from patients who
had undergone repeated medical evalua-
tions by the investigators.
The six iPSC lines studied were differ-
entiated first into NPCs and then iDA
neurons. The GD1, GD1-PD, and GD2
samples had appropriately low GCase ac-
tivity and GCase protein levels at different
neurodevelopmental stages, which re-
sulted in substrate accumulation, GlcCer
and GlcSph.
It has been shown that dopaminergic
neurons with mutant Parkin exhibit in-
creased transcription of monoamine oxi-
dases, increased DA release, and reduced
DA uptake (Jiang et al., 2012). In contrast
Figure 4. Dopamine release and uptake in iPSC-derived GD iDA neurons. A, DA and 3,4-dihydroxyphenylacetic acid (DOPAC)
weremeasured in iDAneurons. Data represent two independent experiments in triplicates: ***p0.0038; ***p0.0016; *p
0.043.B, Dopamineuptake in iDAneurons in thepresence andabsenceof 10 and20MGBR12909, usedas a specific DAT inhibitor.
Graph represents data from three independent experiments in pentaplicates: *p 0.043; ***p 0.0042. C, E, Immunofluores-
cence analyses of GD1, GD2, or GD1-PD iDA neurons after 100 d in culture costained for TH (green), DAT1 (red) (C), or VMAT2 (red)
(E). Insets, Single-channel DAT1 or VMAT2. Scale bars, 5 m. D, F, RT-PCR analysis of DAT1 in NPCs and iDA neurons. Graphs
represent two independent experiments. G, Action potential firing in GD2 iDA neurons. Ga, Gb, Whole-cell recordings of spikes
4
evoked by a range of current injections. Gc, Family of current
traces evoked by voltage steps covering a range of potentials
(5 mV increments). Note the presence of transient outward
current characteristic of potassium currents in native DA neu-
rons. Red tracing represents current evoked by step to 0 mV.
Inset, Fast inward Na-mediated component.
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dopaminergic neurons with mutation G2019S in LRRK2 show
reduced DA release (Nguyen et al., 2011). In our study, GD1-PD
iDA neurons appear to have reduced vesicular DA levels and DA
uptake compared with control and GD1 neurons.
The plasma membrane proteins DAT and VMAT2 are es-
sential for DA transmission. DAT rapidly removes DA from
synapses, whereas VMAT2 transfers cytoplasmic DA into ves-
icles for storage and subsequent release. We observed reduced
Figure 5. Small-molecule NCGC607 increases GCase activity and translocation to lysosomes. A, Western blot analysis of GCase in untreated and NCGC6070-treated iDA neurons using green
fluorescentMDW933. Tuj1 was used as the loading control. Imiglucerase (recombinant GCase) was loaded as a positive control.B, Graph represents quantification of the blots in A. C, GCase activity
(percentage control) in iDA neurons in the presence and absence of NCGC607 (3M). Graph represents data from three independent experiments in quadruplicate: **p 0.005; *p 0.02; **p
0.0025.D, Immunofluorescence study of iDA neurons before and after treatmentwith NCGC607 (3M) for 21 d. Cellswere costained for GCase (green), Lamp2 (red), andDAPI (blue). Z-stack images
were acquiredusingaZeiss 510 confocalmicroscope (63magnification). Insets, Highermagnificationof theareas outlined in the images. Scale bars, 5m.E, Thedegreeof colocalization reflected
in Pearson’s coefficient in areas of colocalization using Imaris software. Each data point represents the mean value of at least five cells per field.
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DAT and VMAT2 expression levels in GD1-PD iDA neurons,
which likely contributes to reduced DA uptake in these cells.
Because there is evidence of a reciprocal relationship
between GCase and -syn, one potential strategy for the
treatment of PD involves enhancement of GCase. Although
enzyme replacement therapy successfully treats the non-
neurological symptoms of GD, the treatment is not effective
for neuronopathic GD (Altarescu et al., 2001; Weinreb et al.,
2002) as it does not cross the blood–brain barrier, and there
are reports of patients with GD who developed PD while on
enzyme replacement therapy (Goker-Alpan et al., 2008). Thus,
chemical chaperone therapy has been proposed as an alterna-
tive strategy for both patients with GD and PD. In this study,
we introduce a new noninhibitory small molecule identified
through high throughput screening and structure–activity
relationship studies, NCGC607, which is able to restore GCase
activity and reduce substrate storage in iMacs and iDA
neurons from patients with GD1, GD1-PD, and GD2. Unlike
the iminosugar molecules isofagomine and N-butyl-deoxy-
norjirimycin, commonly proposed as GCase chaperones,
NCGC607 does not inhibit GCase specific activity in vitro or in
cells (Marugan et al., 2012).
-syn aggregation is a pathological hallmark of PD and
associated synucleinopathies. Neuropathologic studies of
brains from subjects with PD with GBA1 mutations reveal
extensive -syn pathology and inclusions, as well as the pres-
ence of GCase in LBs (Goker-Alpan et al., 2010). Moreover,
patients with sporadic PD without GBA1 mutations also have
reduced GCase activity that is associated with increased -syn
levels (Murphy et al., 2014). Although the exact mechanism is
still unknown, it appears that GBA1 mutations play a pivotal
role, reflected in enhanced aggregation of -syn. One theory is
that reduced GCase activity contributes to lysosomal dysfunc-
tion, which may also lead to -syn accumulation (Mazzulli et
al., 2011). Using iPSC-derived DA neurons, we show that
GD1-PD and GD2 iDA neurons indeed do exhibit elevated
levels of -syn. This was not seen in iDA neurons from pa-
tients with GD without PD, which may correspond to the
clinical observation that only a minority of subjects withGBA1
mutations go on to develop parkinsonism.
The study also enabled us to compare the cellular pheno-
type of iDA neurons from patients from GD1 and GD2. As
expected, those from GD2 have greater GCase deficiency and
more glycolipid storage, both of which improved considerably
Figure 6. NCGC607 reduces GlcSph and GlcCer accumulation in GD iDA neurons. A, Levels of different species of glucosylceramide in iDA neurons measured by mass spectrometry. B,
GlcSph and GalSphmeasured in iDA neurons using HPLC/MS/MS. The portion from GalSph is shown in black. C, GlcSph levels. *p 0.013, p 0.047, p 0.034, and p 0.031for GD1–1,
GD1–2, GD1-PD2, and GD2, respectively. **p 0.0034 for GD1-PD1. D, GlcCer levels. *p 0.045, p 0.035, p 0.025, and p 0.02 for GD1–1, GD1–2, GD1-PD1, and GD1-PD2,
respectively, in iDA neurons after treatment with 3M NCGC607 for 21 d. **p 0.0016 for GD2 in iDA neurons after treatment with 3M NCGC607 for 21 d. Graph represents the mean
of two independent experiments (n 6). E, Immunofluorescence staining with antibodies to GlcCer (green), Lamp2 (red), and Map2 (pink) in iDA neurons in the presence and absence
of NCGC607. Nuclei are counterstained with DAPI. Insets, Higher magnification of the areas outlined in the images. Insets stained in pink, Single-channel views of Map2. Scale bars, 5m.
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with NCGC607 treatment. The GD2 line had genotype L444P/
IVS2 1GT, indicating that the small-molecule chaperoned
mutations other than N370S. Remarkably, GD2 iDAs differ
from GD1 in that they accumulated -syn at levels similar to
what is seen in our GD1-PD lines. This was also reported in
brain samples from subjects with GD2 (Mazzulli et al., 2011)
and could be related to the profound GCase deficiency in these
babies. Although parkinsonism is not associated with GD2,
early mortality is universal in these patients.
We then show that our newnoninhibitory chaperoneNCGC607
successfully decreases the elevated-syn levels inGD1-PDandGD2
iDA neurons. Although in control iDA neurons there is minimal
-syn in lysosomes, enhanced colocalization between-syn and the
lysosomal marker Lamp2 is observed in GD1-PD and GD2 iDA
neurons. Treatment with the small-molecule NCGC607 led to re-
duced colocalization, suggesting that this is a direct result of in-
creased lysosomal GCase. Our findings support the theory that
lysosomal dysfunction associated with diminished GCase activity
might contribute to the accumulation of -syn. The study provides
further proof of principle that increasing GCase activity is a viable
strategy for reducing -syn levels.
A unique feature of this work was its focus on patients with
GD with and without parkinsonism. To our knowledge, this is
the first report of the generation and characterization of iPSC-
derived iDA neurons from patients sharing the two pheno-
types compared with subjects with GD alone. Our ability to
pharmacologically correct the phenotype in all three lines pro-
vides validation that the findings observed were not spurious
phenotypes. Furthermore, this is the first introduction of
NCGC607, demonstrating its ability to reverse multiple as-
pects of the cellular and biochemical phenotype in an appro-
priate cell-based assay. Future studies should address the
ability of NCGC607 tomodulate -syn in lines generated from
subjects with other homozygous and heterozygous GBA1 ge-
Figure 7. -Syn levels in iDA neurons are reduced after NCGC607 treatment. A, Immunofluorescence analysis of iDA neurons stained with antibody to TH (green) and-syn (red). Scale
bars, 5m. B, Western blot analysis of-syn levels in iDA neurons after 150 d in culture and treated with 3M NCGC607 for 21 d. Tuj1 was used as the loading control. C, Quantification
of the -syn levels in iDA neurons in the presence and absence of NCGC607. Statistically significant differences between the untreated and treated cells: ***p 0.00017; p 0.0005;
p 0.0002. ###Significant differences between the patient iDA neurons compared with control (n 2). D, mRNA analysis of-syn levels in iDA neurons after 100 d in culture. HPRT was
used as internal control. Graph represents the mean of two independent experiments. E, iDA neurons were costained for-syn (green), Lamp2 (red), and TH (purple) in the absence (left)
and presence (right) of NCGC607 (3M, 21 d). Insets, Higher magnification of the areas outlined in the images. Z-stack images were acquired using a Zeiss 510 confocal microscope (63
magnification). Scale bars, 5 m. F, Colocalization between Lamp2 and -syn was measured for 50 individual cells and Pearson’s coefficient quantified in ROI volume, using Imaris
software.
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notypes, idiopathic PD, as well as synucleinopathies of other
etiologies.
In conclusion, our study shows that GD1, GD1-PD, and
GD2 iDA neurons have reduced GCase activity, decreased in-
tracellular DA and DA uptake, as well as elevated levels of
GlcSph and GlcCer. Lines from subjects with GD1-PD and
GD2 also have increased -syn. Treatment with the new non-
inhibitory small-molecule NCGC607 successfully restored
GCase activity and protein levels and reduced GlcSph and
GlcCer levels in both iMacs and iDA neurons, indicating that
this chemical class has potential for further development as a
therapy for GD, including neuronopathic forms. In addition,
NCGC607 significantly reduced -syn levels in iDA neurons
from subjects with GD1-PD, demonstrating how modulating
lysosomal GCase impacts -syn accumulation. Our results
suggest that compounds targeting GCase may have utility for
the treatment of Parkinson disease.
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